UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
Commission File Number: 000-28453
----------
(Check One): [ ] Form 10-K [X] Form 10-Q
[ ] Form 20-F [ ] Form 11-K [ ] Form N-SAR
For Period Ended: June 30, 2017
------------------------
[ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended:
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION
PROTECT PHARMACEUTICAL CORPORATION
-----------------------------------
Full Name of Registrant
-------------------------
Former Name if Applicable
100 SE 2nd Street, Suite 2000
---------------------------------------------------------
Address of Principal Executive Office (Street and Number)
Miami, Florida 33131
---------------------------
City, State and Zip Code
PART II - RULES 12b-25(b) and (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)
[X] (a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
[X] (b) The subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, 11-K, Form N-SAR, or portion thereof, will be filed
on or before the fifteenth calendar day following the prescribed due date;
or the subject quarterly report or transition report on Form 10-Q, or
portion thereof will be filed on or before the fifth calendar day following
the prescribed due date; and
[ ] (c) The accountant's statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
PART III - NARRATIVE
State below in reasonable detail the reasons why the Form 10-K, 11-K, 20-F,
10-Q, N-SAR, or other transition report or portion thereof, could not be filed
within the prescribed period.
Registrant has been unable to complete its Form 10-Q for the quarter ended June
30, 2017, within the prescribed time because of delays in completing the
preparation of its financial statements and its management discussion and
analysis. Such delays are primarily due to Registrant's management's dedication
of such management's time to business matters. This has taken a significant
amount of management's time away from the preparation of the Form 10-Q and
delayed the preparation of the audited financial statements for the quarter
ended June 30, 2017.
PART IV - OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Jordan Fishman (954) 866-3726
-------------------------------------------------------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), been filed? If answer is no,
identify report(s). [X] YES [ ] NO
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statement to be included in the subject report or portion thereof?
[ ] YES [X] NO
If so, attach an explanation of the anticipated change, both narratively, and,
if appropriate, state the reasons why a reasonable estimate of the results
cannot be made.
PROTECT PHARMACEUTICAL CORPORATION
--------------------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: August 14, 2017 By: /s/ Jordan Fishman
---------------------------------
Jordan Fishman
President